Professor Michael Barry:

The situation in Germany was free pricing on arrival of post-marketing authorisation. It is followed by a negotiation at the end of the year. If those negotiations are not successful then it is referred on to their equivalent of our group. It is called the Institute for Quality and Efficiency in Health Care, IQWiQ. However, not many drugs find their way there because they do come to a settlement in relation to the price of the drug. In general, the access will continue for the vast majority of drugs.